CASP3 and lymphoma: Combinatory treatment with Prexasertib and Venetoclax synergistically induced apoptosis as demonstrated by time-dependent increase in caspase 3/7 cleavage in BCL-2 positive ABC and DH lymphoma cell lines (Fig. 4E).